Fisher Asset Management LLC Sells 81,724 Shares of Azenta, Inc. $AZTA

Fisher Asset Management LLC lessened its stake in shares of Azenta, Inc. (NASDAQ:AZTA) by 11.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 634,697 shares of the company’s stock after selling 81,724 shares during the quarter. Fisher Asset Management LLC owned about 1.38% of Azenta worth $19,536,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. Mechanics Financial Corp boosted its holdings in Azenta by 77.6% in the second quarter. Mechanics Financial Corp now owns 870 shares of the company’s stock worth $27,000 after purchasing an additional 380 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Azenta by 8.9% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,842 shares of the company’s stock valued at $168,000 after buying an additional 396 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Azenta by 41.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,371 shares of the company’s stock valued at $42,000 after buying an additional 403 shares during the period. Allworth Financial LP boosted its stake in shares of Azenta by 29.1% in the 2nd quarter. Allworth Financial LP now owns 2,050 shares of the company’s stock worth $63,000 after buying an additional 462 shares during the last quarter. Finally, Empowered Funds LLC grew its holdings in shares of Azenta by 10.5% in the first quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock worth $225,000 after acquiring an additional 618 shares during the period. 99.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AZTA has been the topic of several research reports. Zacks Research cut Azenta from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 25th. Needham & Company LLC upped their price target on shares of Azenta from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, November 21st. Jefferies Financial Group raised shares of Azenta from a “hold” rating to a “buy” rating and raised their price objective for the stock from $30.00 to $38.00 in a report on Thursday, October 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Azenta in a research report on Monday. Finally, Raymond James Financial increased their price target on shares of Azenta from $35.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 25th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $38.60.

Azenta Stock Up 1.3%

AZTA stock opened at $35.60 on Thursday. The business’s 50-day moving average price is $31.57 and its 200-day moving average price is $30.81. The stock has a market cap of $1.63 billion, a P/E ratio of -27.38 and a beta of 1.29. Azenta, Inc. has a twelve month low of $23.91 and a twelve month high of $55.63.

Azenta (NASDAQ:AZTA) last released its earnings results on Friday, November 21st. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. Azenta had a negative net margin of 10.01% and a positive return on equity of 1.40%. The company had revenue of $159.19 million for the quarter, compared to analysts’ expectations of $156.76 million. During the same quarter last year, the business earned $0.18 EPS. The firm’s revenue was up 5.7% compared to the same quarter last year. On average, equities research analysts expect that Azenta, Inc. will post 0.53 earnings per share for the current fiscal year.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.